NIO Inc.

NIO Inc. (NYSE: NIO) engages in China's premium electric car sector. The firm develops, co-manufactures, and distributes smart and connected luxury electric cars, pushing innovation in next-generation technologies like connectivity, autonomous driving, and artificial intelligence. Its models include the EP9 supercar, ES8, ES6, and EC6.

Key Highlights

• The company reported a 116.64% increase in total revenues to RMB 9.81 billion in Q3FY21 (ended September 30, 2021) compared to RMB 4.53 billion in Q3FY20.
• NIO reported a decline in net losses to RMB 0.84 billion in Q3FY21 from RMB 1.05 billion in Q3FY20.
• The company shipped 3,667 vehicles in October 2021, a 27.5% decline YoY owing to manufacturing line improvements, preparation for new product releases, and significant supply chain volatility.
• The company's ROE and net margins were -11.3% and -8.5% in Q3FY21 vs. the industry median of 1.8% and 6.4%, respectively.
• The stock is currently trading between its critical short-term (50-day) and long-term (200-day) DMA support levels, with the RSI Index at 45.92.
• It is leaning towards the lower band of the 52-week range of USD 30.71 to USD 66.99.
• NIO stock price has declined 29.51% and 19.93% in the past nine and twelve months, respectively.

Technical Price Chart (as of November 19, 2021). Analysis by Kalkine

Conclusion: Considering the significant losses, margins pressure, and technical indicators, we recommend a "Watch" rating on the stock at the current price of USD 38.80, up 1.02% as of November 19, 2021, at 12:02 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

NewAge, Inc.

NewAge, Inc. (NASDAQ: NBEV) is a company that develops, sells, and distributes a portfolio of healthy goods mainly through a direct to customer business model, with the support of a team of brand partners and distributors to advertise and sell the portfolio of brands.

Key Highlights

• The company reported an 84.67% increase in net revenues to USD 349.11 million during 9MFY21 (ended September 30, 2021) compared to USD 189.05 million during 9MFY20.
• In addition, NBEV reported a decline in a net loss to USD 3.10 million during 9MFY21 from USD 35.31 million during 9MFY20.
• Its reinvestment rate and net margin declined to -1.2% and -2.7% in Q3FY21 vs. 8.4% and 14.0% in Q2FY21, respectively.
• On November 16, 2021, NBEV announced the discovery of a novel mechanism of action for combating the effects of ageing and the submission of a new patent to preserve the discovery's originality.
• The stock is currently trading below its key short-term (50-day) and long-term (200-day) DMA support levels, with the RSI Index at 28.74, indicating an oversold zone.
• It is leaning towards the lower band of the 52-week range of USD 1.16 to USD 4.55.
• NBEV's stock price has declined 45.25% and 61.59% in the past six and nine months, respectively.

Technical Price Chart (as of November 19, 2021). Analysis by Kalkine

Conclusion: Considering the macroeconomic conditions, margins pressure, and technical indicators, we recommend a "Watch" rating on the stock at the current price of USD 1.21, down 2.42% as of November 19, 2021, at 12:06 PM ET.

*The reference data in this report has been partly sourced from REFINITIV. 

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.